Complexes comprising a shielding component
AssigneePolypeptide Therapeutic Solutions, S.L.
InventorsTimothy Jon DEMING, Carles Felip LEON, Irene DOLZ PEREZ, Sergio ESTEBAN PEREZ, Lidia HERRERA MUNOZ, Vicent Josep NEBOT CARDA
Life of this patent
Estimating the term…
Abstract
The present invention relates to new polymer complexes comprising at least one anionic poly(methionine sulfoxide)-based copolymer, which are useful as non-viral vectors for delivery of active ingredients, including nucleic acids, to cells.
Claims19
A polymer complex comprising
- a) a positively charged nanoparticle comprising a cationic polymer, a pharmaceutically acceptable salt thereof, or any stereoisomer or mixtures of stereoisomers, either of the compound of cationic polymer, or of any of its pharmaceutically acceptable salts;
- the cationic polymer being covalently or electrostatically bonded with at least one pharmaceutically, veterinary or cosmetically active ingredient;
- and
- b) at least one anionic copolymer selected from
- i. a copolymer comprising substructure I;
- ii. a copolymer comprising substructure II;
- and
- iii. a copolymer comprising substructure III;
- wherein the substructures III, and III are depicted as follows:
- -Am-Bn- Structure I
- —(Bn-Am)p-Bn- Structure II
- -(Am-Bn)p-Am- Structure III
- each instance of A is an amino acid residue is independently selected from methionine sulfoxide, ethionine sulfoxide, S-alkyl-cysteine sulfoxide, S-alkyl cysteine sulfone, S-alkyl homocysteine, S-alkyl homocysteine sulfoxide, glycosylated cysteine, serine, homoserine, homomethionine sulfoxide, sarcosine, glycine, and alanine;
- wherein at least 50 mol % of the A amino acid residues are methionine sulfoxide;
- wherein each instance of B is independently selected from glutamic acid, aspartic acid, and a salt thereof, and
- wherein:
- m is an integer from 20 to 600;
- n is an integer from 5 to 200;
- and
- p is an integer from 1 to 2.
A method for the preparation of a polymer complex which comprises
- a) providing a cationic polymer in a first liquid;
- b) providing at least one pharmaceutically, veterinary or cosmetically active ingredient in a second liquid and mixing it with an anionic copolymer selected from
- i. a copolymer comprising substructure I;
- ii. a copolymer comprising substructure II;
- and
- iii. a copolymer comprising substructure III;
- c) contacting the cationic polymer in the first liquid with the at least one pharmaceutically, veterinary or cosmetically active ingredient and the anionic copolymer in the second liquid to form a shielded nanoparticle;
- wherein the substructures I, II, and III are as defined herein.
(canceled)
A method for diagnosing a disease in an isolated sample from a subject, the method comprising administering to said subject an effective amount of a polymer complex or pharmaceutical composition having one or more imaging agents in the isolated sample of the subject.
Dependencies are inferred from the claim text.